
Melissa A Rolfes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2626170/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1 | Clinical Influenza Testing Practices in Hospitalized Children at United States Medical Centers, 2015-2018. Journal of the Pediatric Infectious Diseases Society, 2022, 11, 5-8. | 0.6 | 2 |
| 2 | Incidence Rates, Household Infection Risk, and Clinical Characteristics of SARS-CoV-2 Infection Among Children and Adults in Utah and New York City, New York. JAMA Pediatrics, 2022, 176, 59. | 3.3 | 92 |
| 3 | Household Transmission and Clinical Features of SARS-CoV-2 Infections. Pediatrics, 2022, 149, . | 1.0 | 20 |
| 4 | mRNA COVIDâ€19 vaccine effectiveness against SARSâ€CoVâ€2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021. Influenza and Other Respiratory Viruses, 2022, 16, 607-612. | 1.5 | 7 |
| 5 | Rates of Severe Influenza-Associated Outcomes Among Older Adults Living With Diabetes—Influenza Hospitalization Surveillance Network (FluSurv-NET), 2012–2017. Open Forum Infectious Diseases, 2022, 9, ofac131. | 0.4 | 10 |
| 6 | Epidemiology, Clinical Characteristics, and Outcomes of Influenza-Associated Hospitalizations in US Children Over 9 Seasons Following the 2009 H1N1 Pandemic. Clinical Infectious Diseases, 2022, 75, 1930-1939. | 2.9 | 17 |
| 7 | SARS-CoV-2 Virus Dynamics in Recently Infected People—Data From a Household Transmission Study. Journal of Infectious Diseases, 2022, 226, 1699-1703. | 1.9 | 2 |
| 8 | Relative and Absolute Effectiveness of High-Dose and Standard-Dose Influenza Vaccine Against Influenza-Related Hospitalization Among Older Adults—United States, 2015–2017. Clinical Infectious Diseases, 2021, 72, 995-1003. | 2.9 | 29 |
| 9 | Influenza-Associated Medical Visits Prevented by Influenza Vaccination in Young Children in Thailand, 2012–2014. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 349-351. | 0.6 | 0 |
| 10 | Implications of Shortened Quarantine Among Household Contacts of Index Patients with Confirmed SARS-CoV-2 Infection — Tennessee and Wisconsin, April–September 2020. Morbidity and Mortality Weekly Report, 2021, 69, 1633-1637. | 9.0 | 16 |
| 11 | Acute Cardiovascular Events Associated With Influenza in Hospitalized Adults. Annals of Internal Medicine, 2021, 174, 583-584. | 2.0 | 6 |
| 12 | Estimating the number of averted illnesses and deaths as a result of vaccination against an influenza pandemic in nine low- and middle-income countries. Vaccine, 2021, 39, 4219-4230. | 1.7 | 1 |
| 13 | Performance of Self-Collected Anterior Nasal Swabs and Saliva Specimens for Detection of SARS-CoV-2 During Symptomatic and Asymptomatic Periods. Open Forum Infectious Diseases, 2021, 8, ofab484. | 0.4 | 2 |
| 14 | Differentiating severe and non-severe lower respiratory tract illness in patients hospitalized with influenza: Development of the Influenza Disease Evaluation and Assessment of Severity (IDEAS) scale. PLoS ONE, 2021, 16, e0258482. | 1.1 | 2 |
| 15 | Reply to Gonzales-Luna and Carlson. Clinical Infectious Diseases, 2020, 70, 357-358. | 2.9 | 0 |
| 16 | Projected Population Benefit of Increased Effectiveness and Coverage of Influenza Vaccination on Influenza Burden in the United States. Clinical Infectious Diseases, 2020, 70, 2496-2502. | 2.9 | 45 |
| 17 | Effects of Influenza Vaccination in the United States During the 2018–2019 Influenza Season. Clinical Infectious Diseases, 2020, 71, e368-e376. | 2.9 | 72 |
| 18 | Priming with MF59 adjuvanted versus nonadjuvanted seasonal influenza vaccines in children – A systematic review and a meta-analysis. Vaccine, 2020, 38, 608-619. | 1.7 | 13 |

MELISSA A ROLFES

| # | Article | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Vaccine Effectiveness Against Influenza-Associated Lower Respiratory Tract Infections in Hospitalized Adults, Louisville, Kentucky, 2010–2013. Open Forum Infectious Diseases, 2020, 7, ofaa262. | 0.4 | 9 |
| 20 | Investigation and Serologic Follow-Up of Contacts of an Early Confirmed Case-Patient with COVID-19, Washington, USA. Emerging Infectious Diseases, 2020, 26, 1671-1678. | 2.0 | 7 |
| 21 | Acute Cardiovascular Events Associated With Influenza in Hospitalized Adults. Annals of Internal Medicine, 2020, 173, 605-613. | 2.0 | 81 |
| 22 | Variability in published rates of influenza-associated hospitalizations: A systematic review, 2007-2018. Journal of Global Health, 2020, 10, 020430. | 1.2 | 13 |
| 23 | Severe Acute Respiratory Syndrome Coronavirus 2 Prevalence, Seroprevalence, and Exposure among Evacuees from Wuhan, China, 2020. Emerging Infectious Diseases, 2020, 26, 1998-2004. | 2.0 | 5 |
| 24 | Impact of community engagement and social support on the outcomes of HIV-related meningitis clinical trials in a resource-limited setting. Research Involvement and Engagement, 2020, 6, 49. | 1.1 | 3 |
| 25 | Enhanced contact investigations for nine early travel-related cases of SARS-CoV-2 in the United States. PLoS ONE, 2020, 15, e0238342. | 1.1 | 22 |
| 26 | First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. Lancet, The, 2020, 395, 1137-1144. | 6.3 | 435 |
| 27 | Update on Rolfes et al, "Effects of Influenza Vaccination in the United States During the 2017–2018 Influenza Seasonâ€: Clinical Infectious Diseases, 2020, 71, 1585-1586. | 2.9 | 10 |
| 28 | Early season pediatric influenza B/Victoria virus infections associated with a recently emerged virus subclade — Louisiana, 2019. American Journal of Transplantation, 2020, 20, 606-609. | 2.6 | 1 |
| 29 | Initial public health response and interim clinical guidance for the 2019 novel coronavirus outbreak — United States, December 31, 2019–February 4, 2020. American Journal of Transplantation, 2020, 20, 889-895. | 2.6 | 46 |
| 30 | Respiratory and Nonrespiratory Diagnoses Associated With Influenza in Hospitalized Adults. JAMA Network Open, 2020, 3, e201323. | 2.8 | 36 |
| 31 | First Mildly III, Nonhospitalized Case of Coronavirus Disease 2019 (COVID-19) Without Viral Transmission in the United States—Maricopa County, Arizona, 2020. Clinical Infectious Diseases, 2020, 71, 807-812. | 2.9 | 33 |
| 32 | Reducing Antibiotic Use in Ambulatory Care Through Influenza Vaccination. Clinical Infectious Diseases, 2020, 71, e726-e734. | 2.9 | 7 |
| 33 | Transmission of SARS-COV-2 Infections in Households - Tennessee and Wisconsin, April-September 2020. Morbidity and Mortality Weekly Report, 2020, 69, 1631-1634. | 9.0 | 94 |
| 34 | Early Season Pediatric Influenza B/Victoria Virus Infections Associated with a Recently Emerged Virus Subclade — Louisiana, 2019. Morbidity and Mortality Weekly Report, 2020, 69, 40-43. | 9.0 | 23 |
| 35 | Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak — United States, December 31, 2019–February 4, 2020. Morbidity and Mortality Weekly Report, 2020, 69, 140-146. | 9.0 | 343 |
| 36 | Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19 — United States, January–February 2020. Morbidity and Mortality Weekly Report, 2020, 69, 245-246. | 9.0 | 369 |

MELISSA A ROLFES

| # | Article | IF | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Transmission of SARS-COV-2 Infections in Households — Tennessee and Wisconsin, April–September 2020. Morbidity and Mortality Weekly Report, 2020, 69, 1631-1634. | 9.0 | 212 |
| 38 | Age-Related Differences in Hospitalization Rates, Clinical Presentation, and Outcomes Among Older Adults Hospitalized With Influenza—U.S. Influenza Hospitalization Surveillance Network (FluSurv-NET). Open Forum Infectious Diseases, 2019, 6, . | 0.4 | 55 |
| 39 | Measurement of birth outcomes in analyses of the impact of maternal influenza vaccination. Influenza and Other Respiratory Viruses, 2019, 13, 547-555. | 1.5 | 5 |
| 40 | Burden of influenza-associated respiratory hospitalizations in the Americas, 2010–2015. PLoS ONE, 2019, 14, e0221479. | 1.1 | 34 |
| 41 | Update: Influenza Activity — United States, September 30, 2018–February 2, 2019. Morbidity and Mortality Weekly Report, 2019, 68, 125-134. | 9.0 | 61 |
| 42 | Estimating Risk to Responders Exposed to Avian Influenza A H5 and H7 Viruses in Poultry, United States, 2014–2017. Emerging Infectious Diseases, 2019, 25, 1011-1014. | 2.0 | 5 |
| 43 | Effects of Influenza Vaccination in the United States During the 2017–2018 Influenza Season. Clinical Infectious Diseases, 2019, 69, 1845-1853. | 2.9 | 218 |
| 44 | Influenza Vaccine Effectiveness in the United States During the 2016–2017 Season. Clinical Infectious Diseases, 2019, 68, 1798-1806. | 2.9 | 90 |
| 45 | Update: Influenza Activity in the United States During the 2018–19 Season and Composition of the 2019–20 Influenza Vaccine. Morbidity and Mortality Weekly Report, 2019, 68, 544-551. | 9.0 | 98 |
| 46 | Notes from the Field: Assessment of State-Level Influenza Season Severity — Minnesota and Utah, 2017–18 Influenza Season. Morbidity and Mortality Weekly Report, 2019, 68, 165-166. | 9.0 | 1 |
| 47 | Estimating the Incidence of Influenza at the State Level — Utah, 2016–17 and 2017–18 Influenza Seasons. Morbidity and Mortality Weekly Report, 2019, 68, 1158-1161. | 9.0 | 2 |
| 48 | Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness. Influenza and Other Respiratory Viruses, 2018, 12, 132-137. | 1.5 | 231 |
| 49 | Non-mumps Viral Parotitis During the 2014–2015 Influenza Season in the United States. Clinical Infectious Diseases, 2018, 67, 493-501. | 2.9 | 33 |
| 50 | Kinetics of Serological Responses in Critically III Patients Hospitalized With 2009 Pandemic Influenza A(H1N1) Virus Infection in Canada, 2009–2011. Journal of Infectious Diseases, 2018, 217, 1078-1088. | 1.9 | 6 |
| 51 | An evaluation and update of methods for estimating the number of influenza cases averted by vaccination in the United States. Vaccine, 2018, 36, 7331-7337. | 1.7 | 18 |
| 52 | Influenza-Associated Parotitis During the 2014–2015 Influenza Season in the United States. Clinical Infectious Diseases, 2018, 67, 485-492. | 2.9 | 8 |
| 53 | Update: Influenza Activity — United States and Worldwide, May 20–October 13, 2018. Morbidity and Mortality Weekly Report, 2018, 67, 1178-1185. | 9.0 | 15 |
| 54 | Differences in Immunologic Factors Among Patients Presenting with Altered Mental Status During Cryptococcal Meningitis. Journal of Infectious Diseases, 2017, 215, 693-697. | 1.9 | 20 |

MELISSA A ROLFES

| # | Article | IF | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 55 | Efficacy of trivalent influenza vaccine against laboratory-confirmed influenza among young children in a randomized trial in Bangladesh. Vaccine, 2017, 35, 6967-6976. | 1.7 | 14 |
| 56 | Neurocognitive function in HIV-infected persons with asymptomatic cryptococcal antigenemia: a comparison of three prospective cohorts. BMC Neurology, 2017, 17, 110. | 0.8 | 13 |
| 57 | Human Immune Response Varies by the Degree of Relative Cryptococcal Antigen Shedding. Open Forum Infectious Diseases, 2016, 3, ofv194. | 0.4 | 18 |
| 58 | Respiratory Viral Testing and Influenza Antiviral Prescriptions During Hospitalization for Acute Respiratory Illnesses. Open Forum Infectious Diseases, 2016, 3, ofv216. | 0.4 | 11 |
| 59 | Cerebrospinal Fluid Culture Positivity and Clinical Outcomes After Amphotericin-Based Induction Therapy for Cryptococcal Meningitis. Open Forum Infectious Diseases, 2015, 2, ofv157. | 0.4 | 22 |
| 60 | Epidemiology of Meningitis in an HIV-Infected Ugandan Cohort. American Journal of Tropical Medicine and Hygiene, 2015, 92, 274-279. | 0.6 | 60 |
| 61 | Early ART After Cryptococcal Meningitis Is Associated With Cerebrospinal Fluid Pleocytosis and Macrophage Activation in a Multisite Randomized Trial. Journal of Infectious Diseases, 2015, 212, 769-778. | 1.9 | 60 |
| 62 | Cellular Immune Activation in Cerebrospinal Fluid From Ugandans With Cryptococcal Meningitis and Immune Reconstitution Inflammatory Syndrome. Journal of Infectious Diseases, 2015, 211, 1597-1606. | 1.9 | 55 |
| 63 | Standardized Electrolyte Supplementation and Fluid Management Improves Survival During Amphotericin Therapy for Cryptococcal Meningitis in Resource-Limited Settings. Open Forum Infectious Diseases, 2014, 1, ofu070. | 0.4 | 36 |
| 64 | Multisite Validation of Cryptococcal Antigen Lateral Flow Assay and Quantification by Laser Thermal Contrast. Emerging Infectious Diseases, 2014, 20, 45-53. | 2.0 | 253 |
| 65 | The Effect of Therapeutic Lumbar Punctures on Acute Mortality From Cryptococcal Meningitis. Clinical Infectious Diseases, 2014, 59, 1607-1614. | 2.9 | 145 |
| 66 | Cryptococcus neoformans Ex Vivo Capsule Size Is Associated With Intracranial Pressure and Host Immune Response in HIV-associated Cryptococcal Meningitis. Journal of Infectious Diseases, 2014, 209, 74-82. | 1.9 | 90 |
| 67 | Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study. Metabolic Brain Disease, 2014, 29, 269-279. | 1.4 | 45 |
| 68 | Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis. New England Journal of Medicine, 2014, 370, 2487-2498. | 13.9 | 387 |
| 69 | Supply of neuraminidase inhibitors related to reduced influenza <scp>A</scp> (<scp>H</scp> 1 <scp>N</scp> 1) mortality during the 2009–2010 <scp>H</scp> 1 <scp>N</scp> 1 pandemic: summary of an ecological study. Influenza and Other Respiratory Viruses, 2013, 7, 82-86. | 1.5 | 7 |
| 70 | Cryptococcal Meningitis Treatment Strategies in Resource-Limited Settings: A Cost-Effectiveness Analysis. PLoS Medicine, 2012, 9, e1001316. | 3.9 | 79 |
| 71 | Cryptococcal Genotype Influences Immunologic Response and Human Clinical Outcome after Meningitis. MBio, 2012, 3, . | 1.8 | 79 |
| 72 | Development of Clinical Immunity to Malaria in Highland Areas of Low and Unstable Transmission. American Journal of Tropical Medicine and Hygiene, 2012, 87, 806-812. | 0.6 | 20 |

| # | Article | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 73 | Supply of Neuraminidase Inhibitors Related to Reduced Influenza A (H1N1) Mortality during the 2009–2010 H1N1 Pandemic: An Ecological Study. PLoS ONE, 2012, 7, e43491. | 1.1 | 9 |
| 74 | Detection and Stability of SARS-CoV-2 in Three Self-Collected Specimen Types: Flocked Midturbinate Swab (MTS) in Viral Transport Media, Foam MTS, and Saliva. Microbiology Spectrum, 0, , . | 1.2 | 1 |